Pharnext SCA
OTC:PNEXF

Watchlist Manager
Pharnext SCA Logo
Pharnext SCA
OTC:PNEXF
Watchlist
Price: 999 999.9999 USD Market Closed
Market Cap: 6T USD
Have any thoughts about
Pharnext SCA?
Write Note

Pharnext SCA
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pharnext SCA
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Pharnext SCA
OTC:PNEXF
EPS (Diluted)
-€26.3m
CAGR 3-Years
96%
CAGR 5-Years
86%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
EPS (Diluted)
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
EPS (Diluted)
€0
CAGR 3-Years
22%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
EPS (Diluted)
-€2
CAGR 3-Years
-23%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
EPS (Diluted)
€0
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
OSE Immunotherapeutics SA
PAR:OSE
EPS (Diluted)
€1
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pharnext SCA
Glance View

Market Cap
6T USD
Industry
Biotechnology

Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Suresnes, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.

PNEXF Intrinsic Value
Not Available

See Also

What is Pharnext SCA's EPS (Diluted)?
EPS (Diluted)
-26.3m EUR

Based on the financial report for Jun 30, 2023, Pharnext SCA's EPS (Diluted) amounts to -26.3m EUR.

What is Pharnext SCA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
86%

Over the last year, the EPS (Diluted) growth was 100%. The average annual EPS (Diluted) growth rates for Pharnext SCA have been 96% over the past three years , 86% over the past five years .

Back to Top